Bachem renews supply contract with AstraZeneca

Bachem renews supply contract with AstraZeneca
Bubendorf/Basel, August 9, 2011 - Bachem (SIX: BANB) today announced the renewal of a supply agreement with AstraZeneca, thereby extending the existing agreement between both companies. Bachem has been supplying Goserelin to AstraZeneca for more than 20 years.
Under the terms of the agreement, AstraZeneca will continue to acquire the peptide active ingredient Goserelin from Bachem for the next seven years.

Dr. Lester Mills, Chief Marketing Officer of the Bachem Group, commented: „This renewed long-term sales agreement for Goserelin is a statement of our competitive capabilities and a strong confirmation of our motto Quality Matters. We are looking forward to the continued
collaboration with AstraZeneca as part of a very successful and already long-standing partnership."

About Bachem
Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes.

With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.
For further questions, please contact:
Bachem Holding AG
Stephan Schindler, CFO
Tel.: +41 61 935 2333
Fax: +41 61 935 2324
[email protected]
www.bachem.com

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.